Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma
In: ISSN: 0378-5173 ; International Journal of Pharmaceutics ; https://univ-angers.hal.science/hal-03774820 ; International Journal of Pharmaceutics, 2022, 626, pp.122164. ⟨10.1016/j.ijpharm.2022.122164⟩ ; https://www.sciencedirect.com/science/article/abs/pii/S0378517322007189?via%3Dihub, 2022
Online
academicJournal
Zugriff:
International audience ; Ovarian cancer is one of the deadliest epithelial malignancies in women, owing to the multidrug resistance that restricts the success of conventional chemotherapy, carboplatin and paclitaxel. High grade serous ovarian carcinoma can be classified into two subtypes, the chemosensitive High OXPHOS and the Low OXPHOS tumour, less sensitive to chemotherapy. This difference of treatment efficacy could be explained by the redox status of these tumours, High OXPHOS exhibiting a chronic oxidative stress and an accumulation of reactive oxygen species. Ferrocifens, bio-organometallic compounds, are believed to be ROS producers with a good cytotoxicity on ovarian cancer cell lines. The aim of this study was to evaluate the in vivo efficacy of ferrocifen stealth lipid nanocapsules on High and Low OXPHOS ovarian Patient-Derived Xenograft models, alone or in combination to standard chemotherapy. Accordingly, two ferrocifens, P53 and P722, were encapsulated in stealth LNCs. The treatment by stealth P722-LNCs in combination with standard chemotherapy induced, with a concentration eight time lower than in stealth P53-LNCs, similar tumour reduction on a Low OXPHOS model, allowing us to conclude that P722 could be a leading ferrocifen to treat ovarian cancer. This combination of treatments may represent a promising synergistic approach to treat resistant ovarian adenocarcinoma.
Titel: |
Ferrocifen stealth LNCs and conventional chemotherapy: A promising combination against multidrug-resistant ovarian adenocarcinoma
|
---|---|
Autor/in / Beteiligte Person: | Idlas, Pierre ; Ladaycia, Abdallah ; Némati, Fariba ; Lepeltier, Elise ; Pigeon, Pascal ; Jaouen, Gerard ; Decaudin, Didier ; Passirani, Catherine ; Micro et Nanomédecines Translationnelles (MINT) ; Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS) ; Laboratory of Preclinical Investigation, Department of Translational Research ; Institut Curie Research Center ; Institut Parisien de Chimie Moléculaire (IPCM) ; Chimie Moléculaire de Paris Centre (FR 2769) ; École normale supérieure - Paris (ENS-PSL) ; Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP) ; Université Paris Sciences et Lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris) ; Université Paris Sciences et Lettres (PSL)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL) ; Université Paris Sciences et Lettres (PSL)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS) ; Chemical Biology (CHEMBIO) ; Université Paris Sciences et Lettres (PSL)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Chimie Moléculaire de Paris Centre (FR 2769) ; Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP) ; Université Paris Sciences et Lettres (PSL) ; Department of Medical Oncology, Institut Curie, Paris 75248, France ; ANR-19-CE18-0022,NaTeMOc,Nanoformulation et évaluation thérapeutique d'un nouveau complexe bioorganométallique à fort potentiel antitumoral pour le cancer ovarien(2019) |
Link: | |
Zeitschrift: | ISSN: 0378-5173 ; International Journal of Pharmaceutics ; https://univ-angers.hal.science/hal-03774820 ; International Journal of Pharmaceutics, 2022, 626, pp.122164. ⟨10.1016/j.ijpharm.2022.122164⟩ ; https://www.sciencedirect.com/science/article/abs/pii/S0378517322007189?via%3Dihub, 2022 |
Veröffentlichung: | HAL CCSD ; Elsevier, 2022 |
Medientyp: | academicJournal |
DOI: | 10.1016/j.ijpharm.2022.122164 |
Schlagwort: |
|
Sonstiges: |
|